NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
Clinical Trials
12 trialsNCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT04450836 2025-03-30
SOREGATT
UNICANCER
Phase 2 Terminated
NCT02581059 2024-06-26
Efficacy of Ginseng for Patients on Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02383433 2023-10-23
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03099486 2022-02-07
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Fox Chase Cancer Center
Phase 2 Terminated
NCT04476329 2021-12-30
ReDos HCC
SC Liver Research Consortium, LLC
Phase 2 Terminated
NCT02425683 2020-02-10
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
Phase 2 Terminated
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated
NCT02241720 2018-01-11
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
University of Utah
Phase 2 Terminated
NCT02278783 2017-10-06
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
University of Utah
Phase 2 Terminated
NCT02175654 2017-08-01
PREVIUM
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Terminated